Digital Pathology and Artificial Intelligence Applied to Nonclinical Toxicology Pathology-The Current State, Challenges, and Future Directions.

IF 1.4 4区 医学 Q3 PATHOLOGY
Gabriele Pohlmeyer-Esch, Charles Halsey, Julie Boisclair, Sripad Ram, Sarah Kirschner-Kitz, Brian Knight, Pierre Moulin, Anna-Lena Frisk
{"title":"Digital Pathology and Artificial Intelligence Applied to Nonclinical Toxicology Pathology-The Current State, Challenges, and Future Directions.","authors":"Gabriele Pohlmeyer-Esch, Charles Halsey, Julie Boisclair, Sripad Ram, Sarah Kirschner-Kitz, Brian Knight, Pierre Moulin, Anna-Lena Frisk","doi":"10.1177/01926233251340622","DOIUrl":null,"url":null,"abstract":"<p><p>Advancements in digital pathology and artificial intelligence (AI) have enormous transformative potential for nonclinical toxicologic pathology and are already changing the ways in which pathologists work. However, due to the rapid evolution of digital pathology and AI, the toxicologic pathology community would benefit from an update on these advancements, which can be used to aid drug development. Here we identify key articles published on the use of digital pathology and AI in the field and provide current regulatory statuses and guidelines. For digital pathology, we outline the requirements for equipment, validation processes, workflows, and archiving. Challenges to achieve system interoperability and to establish harmonization through Digital Imaging and Communications in Medicine compatibility are also discussed. For AI, we highlight considerations for model development, including the determination of ground truth, problems that may arise due to bias, and how the accuracy and precision of AI algorithms can be assessed. Finally, we discuss the challenges and potential for AI-assisted toxicologic pathology, picturing a future where technology and scientific expertise work hand-in-hand to improve the quality and efficiency of nonclinical drug safety evaluation. This publication is a deliverable of the European Innovative Medicines Initiative 2 Joint Undertaking, \"Bigpicture.\"</p>","PeriodicalId":23113,"journal":{"name":"Toxicologic Pathology","volume":" ","pages":"1926233251340622"},"PeriodicalIF":1.4000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Toxicologic Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/01926233251340622","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Advancements in digital pathology and artificial intelligence (AI) have enormous transformative potential for nonclinical toxicologic pathology and are already changing the ways in which pathologists work. However, due to the rapid evolution of digital pathology and AI, the toxicologic pathology community would benefit from an update on these advancements, which can be used to aid drug development. Here we identify key articles published on the use of digital pathology and AI in the field and provide current regulatory statuses and guidelines. For digital pathology, we outline the requirements for equipment, validation processes, workflows, and archiving. Challenges to achieve system interoperability and to establish harmonization through Digital Imaging and Communications in Medicine compatibility are also discussed. For AI, we highlight considerations for model development, including the determination of ground truth, problems that may arise due to bias, and how the accuracy and precision of AI algorithms can be assessed. Finally, we discuss the challenges and potential for AI-assisted toxicologic pathology, picturing a future where technology and scientific expertise work hand-in-hand to improve the quality and efficiency of nonclinical drug safety evaluation. This publication is a deliverable of the European Innovative Medicines Initiative 2 Joint Undertaking, "Bigpicture."

数字病理学和人工智能在非临床毒理学病理学中的应用——现状、挑战和未来方向。
数字病理学和人工智能(AI)的进步对非临床毒理学病理学具有巨大的变革潜力,并且已经改变了病理学家的工作方式。然而,由于数字病理学和人工智能的快速发展,毒理学病理学界将从这些进步的更新中受益,这些进步可用于帮助药物开发。在这里,我们确定了发表的关于数字病理学和人工智能在该领域使用的关键文章,并提供了当前的监管状况和指南。对于数字病理学,我们概述了对设备、验证过程、工作流程和存档的要求。还讨论了实现系统互操作性和通过医学兼容性中的数字成像和通信建立协调的挑战。对于人工智能,我们强调了模型开发的考虑因素,包括确定基本事实、可能因偏见而产生的问题,以及如何评估人工智能算法的准确性和精度。最后,我们讨论了人工智能辅助毒理学病理学的挑战和潜力,描绘了技术和科学专业知识携手合作以提高非临床药物安全性评估质量和效率的未来。本出版物是欧洲创新药物倡议联合事业“大图景”的可交付成果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Toxicologic Pathology
Toxicologic Pathology 医学-病理学
CiteScore
4.70
自引率
20.00%
发文量
57
审稿时长
6-12 weeks
期刊介绍: Toxicologic Pathology is dedicated to the promotion of human, animal, and environmental health through the dissemination of knowledge, techniques, and guidelines to enhance the understanding and practice of toxicologic pathology. Toxicologic Pathology, the official journal of the Society of Toxicologic Pathology, will publish Original Research Articles, Symposium Articles, Review Articles, Meeting Reports, New Techniques, and Position Papers that are relevant to toxicologic pathology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信